<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/0EE529AB-46E7-4F14-B881-5255B40C5ECA" ns1:id="0EE529AB-46E7-4F14-B881-5255B40C5ECA"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/3DAA3F97-C9CE-4821-810D-B4A3BF066439" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/EC9326B5-50D8-459F-9932-1D39B5055FC9" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/EC9326B5-50D8-459F-9932-1D39B5055FC9" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2026-12-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/6EE008AD-65D7-490C-A90C-39F96F4B5E1C" ns1:rel="FUND" ns1:start="2023-01-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10058101</ns2:identifier></ns2:identifiers><ns2:title>Imminent Disease Prediction and Prevention at the Environment Host Interface (IMMEDIATE)</ns2:title><ns2:status>Active</ns2:status><ns2:grantCategory>EU-Funded</ns2:grantCategory><ns2:leadFunder>Horizon Europe Guarantee</ns2:leadFunder><ns2:abstractText>IMMEDIATE aims to investigate and explore the diet-microbiome-immunometabolism-axis as a sensor for health-to-disease transition and evaluate strategies to maintain an individual’s well-being. Chronic inflammation is the major root of most diseases. Understanding of this process preceding organ dysfunction or damage and identification of biomarkers in the pre-symptomatic stage and risk but also resilience factors of health-to-disease transition will enable targeted and personalized interventions to prevent irreversible organ damage. Metabolites of gut microbiota are key messengers between diet, microbiota and host, maintaining the balance of pro- and anti-inflammation. Our study takes advantage of cutting-edge omics technologies available within the IMMEDIATE consortium in conjunction with available clinical data and biospecimens from ongoing observational studies, enrolling “healthy” subjects and individualsin the pre-disease stage but with largely distinct environmental and dietary modulators, including a cohort of kidney transplant recipients in whom renal function has been “reset to baseline”. The identification of clinical and omics-derived biomarkers will – by employing AI algorithms - yield a personalized risk / resilience score of chronic inflammation and thus a better prediction of an individual’s risk of transition towards disease. A proof-of-concept intervention study with the anti-inflammatory microbe Akkermansia muciniphila will be conducted to test whether deflections of the microbiome-metabolite-immune axis can be reverted on the biomarker level but also with respect to clinical outcomes and overall well-being. Mobile apps developed by the IMMEDIATE consortium in collaboration with patient organizations tracking numerous lifestyle-related measures and providing guidance and feedback on these aspects will empower individuals to adopt and integrate these knowledge-based health interventions into their own lives, hereby selfmanaging their own health.</ns2:abstractText></ns2:project>